Ultrasound-Guided PRP Enters a Controlled Test for Traumatic Peripheral Nerve Injury
A prospective nonrandomized trial in Egypt is testing whether platelet-rich plasma delivered under ultrasound guidance can improve recovery after traumatic peripheral nerve injury. The study pairs a targeted biologic intervention with routine rehabilitation, then tracks whether motor function, electrophysiology, and muscle appearance improve over six months.
The design is straightforward, but the clinical question is not. Peripheral nerve trauma often leaves patients with prolonged weakness even after the initial injury has stabilized, because axonal injury, impaired reinnervation, and muscle denervation can persist well beyond the acute event. In that setting, a local biologic therapy aimed at the injured nerve and denervated muscles is meant to do more than relieve symptoms; it is intended to support regeneration at the level where recovery actually occurs.
How the Study Is Structured Around Recovery Biology
Sixty adults are planned for enrollment, with 30 assigned to the PRP intervention and 30 managed with rehabilitation alone. The trial is non-randomized and uses single masking of the outcomes assessor, a design that preserves some objectivity in outcome measurement even though treatment allocation is not randomized. Participants must be 18 to 45 years old and have clinical evidence of peripheral nerve injury, electrophysiologic confirmation on nerve conduction studies, and ultrasound evidence of complete or partial continuity, neuroma, or entrapment. A stable neurologic deficit for at least four weeks is required before enrollment.
The exclusion criteria narrow the cohort toward patients most likely to have a measurable recovery signal without confounding from very different nerve pathologies. Complete nerve transection without surgical repair is excluded, as are active infection, coagulopathy or platelet disorders, and prior regenerative injection therapy to the affected nerve. Those restrictions matter because PRP depends on platelet-derived growth factors and local tissue responsiveness; severe structural discontinuity or uncontrolled bleeding risk would distort both safety and interpretability.
The intervention itself is US-guided PRP injection into the injured nerve and denervated muscles, combined with usual rehabilitation. Control participants receive rehabilitation alone. Ultrasound guidance is more than a convenience here. It is the mechanism that allows the injector to localize treatment to the pathologic segment, avoid scattershot placement, and align the biologic dose with the anatomy of the lesion rather than relying on blind percutaneous delivery.
Strength Change Is the Primary Endpoint
The primary endpoint is change in muscle strength using the Medical Research Council scale, scored from 0 to 5. Baseline assessment is repeated every three weeks through week 24, with evaluations at 3 and 6 months. A stronger MRC score would suggest that reinnervation is translating into bedside function, not merely into better-looking imaging or isolated nerve signals.
That endpoint is clinically sensible because patients do not experience peripheral nerve recovery as a laboratory phenomenon. They experience it as the ability to lift a wrist, extend a finger, dorsiflex a foot, or generate enough force to return to daily tasks. In peripheral nerve injury, even a small gain on the MRC scale can represent a meaningful shift in independence, especially when denervated muscles are at risk of wasting during the long wait for axonal regrowth.
Electrophysiology and Ultrasound Add Biological Specificity
Secondary outcomes bring a more granular view of recovery. One is change in compound muscle action potential amplitude on nerve conduction studies at baseline, 3 months, and 6 months. CMAP amplitude reflects the number of functioning motor axons reaching the muscle, so improvement would support the idea that treatment is affecting nerve conduction and axonal integrity rather than simply masking weakness.
A second electrophysiologic endpoint examines voluntary motor unit recruitment on needle EMG, graded from absent to full interference pattern. That measure can capture whether a partially denervated muscle is recruiting more motor units during maximal contraction. If recruitment improves before obvious strength gains, it may reveal early reinnervation that precedes visible functional recovery.
The third secondary endpoint is muscle echogenicity on ultrasound, measured as mean grayscale intensity at a standardized site using consistent imaging settings. Denervated muscle often undergoes structural and compositional changes that alter its appearance on ultrasound. A lower or normalized echogenicity pattern could suggest that the tissue is moving away from chronic denervation changes, though imaging alone cannot prove physiologic recovery. The combination of ultrasound, EMG, and MRC scoring creates a layered assessment of the same process from different angles.
Why PRP Remains Plausible but Unproven
PRP has attracted attention in regenerative medicine because it concentrates platelet-derived growth factors that may influence inflammation, tissue repair, and cellular signaling. In peripheral nerve injury, that biologic profile is attractive for a simple reason: regeneration depends on a coordinated repair cascade involving Schwann cells, axonal sprouting, and the survival of the target muscle while reinnervation is pending. Delivering PRP near the injured nerve may help create a local environment that supports that cascade.
Still, the appeal of the mechanism does not guarantee clinical benefit. Peripheral nerve regeneration is influenced by injury severity, lesion location, timing of intervention, and the extent of muscle denervation before treatment begins. A nonrandomized design can also leave room for selection effects, especially when patients with different trajectories are compared across arms. The masked assessor helps, but it cannot fully neutralize baseline differences that may shape recovery.
What the Trial Can and Cannot Answer Yet
This study can determine whether ultrasound-guided PRP is associated with better strength recovery and improved objective nerve measures over six months in a relatively narrow adult population. It can also clarify whether the intervention is feasible alongside standard rehabilitation in a real-world hospital setting in Cairo.
It cannot yet establish comparative efficacy at the level of a randomized controlled trial, and it does not provide results at this stage. The trial will also leave open whether any observed benefit depends on a specific type of nerve injury, whether ultrasound-based targeting is essential to the response, or whether the same approach would translate to patients older than 45 years or to more severe lesions with full discontinuity.
For now, the value of the study lies in its anatomical precision and its clinically grounded endpoints. Peripheral nerve injury recovery is often judged too late and too crudely. By measuring strength, nerve conduction, motor unit recruitment, and muscle echogenicity in parallel, this trial is set up to show whether a local biologic injection can move recovery beyond rehabilitation alone.